


Supplemental Figure 1. Study attrition



Abbreviations: 1L, first-line treatment; aPD-1, anti-PD1 monotherapies; BRAF/MEKi, BRAF/MEK combination therapy; USON, US Oncology Network

†As the initial study dataset was generated for an expanded study of melanoma treatment patterns, patients included in this count initiated 1L treatment with any anticancer regimen or received pembrolizumab in any line of therapy.